Option Care Health (NASDAQ:OPCH) Releases Q4 2024 Earnings Guidance

Option Care Health (NASDAQ:OPCH - Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided EPS guidance of 0.420-0.450 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.

Option Care Health Trading Up 15.5 %

NASDAQ:OPCH traded up $3.73 during trading hours on Monday, hitting $27.72. 5,927,819 shares of the company were exchanged, compared to its average volume of 2,115,454. Option Care Health has a one year low of $21.39 and a one year high of $34.63. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. The company has a fifty day simple moving average of $23.20 and a 200 day simple moving average of $27.69.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Truist Financial cut their target price on Option Care Health from $41.00 to $34.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Jefferies Financial Group lowered Option Care Health from a "buy" rating to a "hold" rating and dropped their price target for the stock from $38.00 to $26.00 in a report on Thursday, October 31st. JMP Securities reissued a "market outperform" rating and set a $30.00 target price (down from $31.00) on shares of Option Care Health in a research report on Friday. Bank of America raised shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their price objective for the company from $26.00 to $33.00 in a report on Monday. Finally, The Goldman Sachs Group cut Option Care Health from a "buy" rating to a "neutral" rating and decreased their price target for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.71.

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of the stock in a transaction on Friday, November 8th. The stock was acquired at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the completion of the purchase, the director now owns 326,334 shares of the company's stock, valued at $7,355,568.36. This represents a 15.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.64% of the stock is currently owned by company insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.